新云社 update: Grand Pharma has completed enrollment of the first patient in a domestic Phase II clinical trial of GPN01020, a Class 1.1 traditional Chinese medicine innovative drug for migraine prophylaxis. The candidate was developed from a hospital preparation and is now entering evidence-based verification after long-term clinical experience. The company called the dosing a milestone for its otorhinolaryngology TCM portfolio.
Grand Pharma’s Migraine Prevention TCM Drug Doses First Patient in Phase II Trial
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
38m ago
Bitcoin falls to intraday low of $55,555.55 on Binance
42m ago
Bit Digital Deposits 16,639 ETH to Galaxy Digital, Sitting on $237M Unrealized Loss
45m ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
49m ago
Ethereum Falls Out of Top 100 Global Assets by Market Cap
58m ago
Two Traders Liquidated for Combined $36.09M in BTC, ETH
1h ago
Kiyosaki Says He’ll Wait for Bitcoin Bottom Before Buying




